These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36052821)

  • 1. A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1).
    Zhang L; Poland B; Green M; Wong S; Slatter JG
    Xenobiotica; 2022 Jun; 52(6):555-566. PubMed ID: 36052821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects.
    Wong S; Krejsa C; Lee D; Harris A; Simard E; Wang X; Allard M; Podoll T; O'Reilly T; Slatter JG
    Clin Pharmacol Drug Dev; 2022 May; 11(5):640-653. PubMed ID: 35172043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
    Verstovsek S; Al-Ali HK; Mascarenhas J; Perkins A; Vannucchi AM; Mohan SR; Scott BL; Woszczyk D; Koschmieder S; García-Delgado R; László R; McGreivy JS; Rothbaum WP; Kiladjian JJ
    Future Oncol; 2022 Nov; ():. PubMed ID: 36416118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth
    Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
    Cancer Res Commun; 2022 Sep; 2(9):1075-1088. PubMed ID: 36922937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.
    Wang T; Xie J; Wang Y; Zheng X; Lei J; Wang X; Dong H; Yang Q; Chen L; Xing J; Dong Y
    Pharmacotherapy; 2015 Sep; 35(9):797-804. PubMed ID: 26406771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents.
    Sato N; Suzuki H; Hayashi H; Shibasaki S; Sugano T; Maebashi K; Kurosawa T; Shiomi M; Ogata H
    Jpn J Antibiot; 2008 Oct; 61(5):314-38. PubMed ID: 19260351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic evaluation of marbofloxacin after intravenous administration at different ages in llama crias, and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation.
    Rubio-Langre S; Aguilar-Sola S; Lorenzutti AM; San Andrés MI; De Lucas JJ; Litterio NJ
    J Vet Pharmacol Ther; 2018 Dec; 41(6):861-870. PubMed ID: 30020535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-Based Pharmacokinetics and Dose Optimization of Imipenem in Vietnamese Critically-Ill Patients.
    Dinh TD; Nguyen HN; Le BH; Nguyen TTT; Nguyen HTL
    Infect Drug Resist; 2022; 15():4575-4583. PubMed ID: 36003989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers.
    Li YF; Wang K; Yin F; He YC; Huang JH; Zheng QS
    Acta Pharmacol Sin; 2012 Nov; 33(11):1424-30. PubMed ID: 22864303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period.
    Dong M; Fukuda T; Cox S; de Vries MT; Hooper DK; Goebel J; Vinks AA
    Br J Clin Pharmacol; 2014 Nov; 78(5):1102-12. PubMed ID: 24837828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics.
    Kitamura Y; Yoshida K; Kusama M; Sugiyama Y
    Drug Metab Pharmacokinet; 2014; 29(6):455-62. PubMed ID: 25008846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics and Pharmacodynamics Modelling of Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.
    Yang S; Dumitrescu TP
    Drugs R D; 2017 Mar; 17(1):145-158. PubMed ID: 28004376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentration-Dependent Activity of Pazufloxacin against
    Umezaki Y; Matsumoto K; Ikawa K; Yokoyama Y; Enoki Y; Shigemi A; Watanabe E; Nakamura K; Ueno K; Terazono H; Morikawa N; Takeda Y
    Antibiotics (Basel); 2022 Jul; 11(7):. PubMed ID: 35884236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: an integrated parent-metabolite model.
    Ortega F; Quintana A; Suárez E; Lukas JC; Jauregizar N; de la Fuente L; Lucero ML; Gonzalo A; Orjales A; Calvo R
    Pharm Res; 2005 Nov; 22(11):1769-82. PubMed ID: 16158214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.